AbbVie is reaching for the Sky(rizi) as it spent a staggering $51.5 million on TV drug ads for its immunology blockbuster in October. | AbbVie is reaching for the Sky(rizi) as it spent a staggering ...

Johnson & Johnson (NYSE: JNJ) announced today that 43 presentations showcasing the Company's rheumatology pipeline and portfolio will be featured at the American College of Rheumatology (ACR) 2024 ...

RYTELO™ (imetelstat) is FDA approved for the treatment of low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent ...

Significant contributors to Royalty Pharma’s financial success include strong performances from Trelegy, Evrysdi, and Tremfya, alongside strategic acquisitions of synthetic royalties for therapies ...

Results from a retrospective cohort study show lower all-cause mortality and fewer hospitalizations and intestinal ...

Amid current economic uncertainties and market volatility, investing in defensive stocks appears as an ideal strategy for ...

We recently compiled a list of the 10 Best Pharma Stocks To Buy Right Now. In this article, we are going to take a look at where Johnson & Johnson (NYSE:JNJ) stands against the other pharma stocks.

Proceeds expected to support the upcoming planned launches and fund the continued development of Niktimvo and revumenibExpected to fund Syndax through profitability; proforma cash approaching $800 mil ...

“Tremfya was [$1 billion] in sales for the quarter … on psoriasis and psoriatic arthritis alone. When we take a look going ...